Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 71,666 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 19,000 · Balance 71,666 F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. |
| Common SharesSEC Table I · non-derivative | IndirectHeld by Quidnet Inc. | 465 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 465 F2: Quidnet Inc. is wholly owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date.
F2: Quidnet Inc. is wholly owned by the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 21:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003805 · ownership.xml · nonDerivative · entry 1 Marshall Patrick · CIK 0001978257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,666 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 01:44 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003594 · ownership.xml · nonDerivative · entry 1 Marshall Patrick · CIK 0001978257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,666 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest in equal proportions over twelve (12) months, commencing on the grant date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 41,666 | $1.92 | $79,998.72 |
DisclosureSEC source: 0001171843-25-000867 · ownership.xml · nonDerivative · entry 1 Marshall Patrick · CIK 0001978257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,666 F1 · price: On February 12, 2025, the Reporting Person purchased in a private placement, 41,666 common shares, without par value, of the Issuer, for a purchase price of $1.92 per share. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009532 · section16.xml · derivative · entry 1 Marshall Patrick · CIK 0001978257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2023-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:45 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009596 · section16.xml · derivative · entry 1 Marshall Patrick · CIK 0001978257 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 12 months beginning on the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.